Elevance Health CEO buys 2,725 company shares

Elevance Health, Inc. President and CEO Gail Boudreaux reported purchases of a total of 2,725 shares of common stock on July 17, 2026.

Rhea-AI Filing Summary

Elevance Health, Inc. President and CEO Gail Boudreaux reported purchases of a total of 2,725 shares of common stock on July 17, 2026. She bought 680 shares at a weighted-average price of $366.41 (with trade prices from $366.14 to $366.48) and 2,045 shares at a weighted-average price of $368.25 (with trade prices from $367.76 to $368.69). After these transactions, she directly holds 171,976 shares and indirectly holds 60 shares through her spouse’s revocable trust. The Rule 10b5-1 trading plan checkbox was not marked for these transactions.

Insider Trade Summary

Net Buyer: 2,725 shares

Net Buy 3 txns

Insider BOUDREAUX GAIL

Role President and CEO

Bought 2,725 shs ($1.00M)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1	680	$366.41	$249K
Purchase	Common Stock F2	2,045	$368.25	$753K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 171,976 shares (Direct); Common Stock — 60 shares (Indirect, Shares Held in Spouse's Revocable Trust)

Footnotes (2)

1. F1. This transaction was executed in multiple purchases at prices ranging from $366.14 to $366.48. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
2. F2. This transaction was executed in multiple purchases at prices ranging from $367.76 to $368.69. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Total shares purchased: 2,725 shares First tranche average price: $366.41 per share Second tranche average price: $368.25 per share +2 more

5 metrics

Total shares purchased 2,725 shares Common stock bought by Gail Boudreaux on July 17, 2026

First tranche average price $366.41 per share 680 shares purchased; trade prices ranged from $366.14 to $366.48

Second tranche average price $368.25 per share 2,045 shares purchased; trade prices ranged from $367.76 to $368.69

Direct holdings after transactions 171,976 shares Directly held Elevance Health common stock following July 17, 2026 purchases

Indirect holdings via revocable trust 60 shares Shares held in spouse's revocable trust reported as indirect ownership

Key Terms

revocable trust, weighted average purchase price, indirect ownership, open market or private transaction

4 terms

revocable trust financial

"Shares held in spouse's revocable trust"

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

weighted average purchase price financial

"The price reported reflects the weighted average purchase price"

The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.

indirect ownership financial

"ownership_type reported as indirect through spouse's revocable trust"

open market or private transaction financial

"Purchase in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider share purchases did ELV CEO Gail Boudreaux report?

Gail Boudreaux reported buying 2,725 shares of Elevance Health common stock on July 17, 2026, in two transactions at weighted-average prices of $366.41 and $368.25, increasing her directly held stake to 171,976 shares.

At what prices did ELV CEO Gail Boudreaux purchase shares?

Gail Boudreaux purchased Elevance Health (ELV) shares at weighted-average prices of $366.41 for 680 shares and $368.25 for 2,045 shares, with individual trade prices ranging from $366.14 to $368.69 across the two transactions.

How many Elevance Health (ELV) shares does Gail Boudreaux now hold?

Following the reported transactions, Gail Boudreaux directly holds 171,976 Elevance Health shares and indirectly holds 60 shares through her spouse’s revocable trust, as of the July 17, 2026 Form 4 filing.

Were Gail Boudreaux’s ELV share purchases under a Rule 10b5-1 plan?

The Form 4 for Elevance Health (ELV) indicates the Rule 10b5-1 checkbox was not marked, meaning these reported July 17, 2026 share purchases were not designated as being made under a Rule 10b5-1 trading plan.

Does Gail Boudreaux have indirect ownership of Elevance Health (ELV) shares?

Yes. In addition to her direct holdings, Gail Boudreaux is reported as having indirect ownership of 60 Elevance Health shares held in her spouse’s revocable trust, according to the Form 4 ownership table.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 01:50 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOUDREAUX GAIL

(Last) (First) (Middle)

220 VIRGINIA AVENUE

(Street)

INDIANAPOLIS INDIANA 46204

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Elevance Health, Inc. [ ELV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/17/2026		P		680	A	$366.41(1)	169,931	D
Common Stock	07/17/2026		P		2,045	A	$368.25(2)	171,976	D
Common Stock								60	I	Shares Held in Spouse's Revocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple purchases at prices ranging from $366.14 to $366.48. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

2. This transaction was executed in multiple purchases at prices ranging from $367.76 to $368.69. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ Kathleen S. Kiefer, Attorney in fact	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)